Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 386 of 5804
-
Engineered TB bacteria could offer new hope for bladder cancer patients
Disease control Recruiting nowThis is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of…
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for Tough-to-Treat blood cancers: NX-5948 trial opens
Disease control Recruiting nowThis is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to t…
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Gene therapy for SMA tested in real-world settings of poorer nations
Disease control Recruiting nowThe study objective is to determine the real-world safety and effectiveness of Vesemnogene lantuparvovec for the treatment of SMA. The specific objectives are: * To determine clinical effectiveness of Vesemnogene lantuparvovec therapy for SMA as evaluated by developmental gross…
Phase: PHASE3 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New study tests simple blood thinner to protect new moms from deadly clots
Prevention Recruiting nowThe goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpar…
Phase: PHASE3 • Sponsor: Marc Blondon • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
Vitamin a derivative patch could reverse oral precancer
Disease control OngoingThe goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific c…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a placenta injection ease your knee pain?
Symptom relief Recruiting nowThis is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis. The purpose of the trial is to evaluate the efficacy, safety, and tolerabi…
Phase: PHASE3 • Sponsor: Doron Therapeutics Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo targets Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a sleep pill ward off Alzheimer's? new trial aims to find out
Prevention Recruiting nowThis study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer'…
Phase: PHASE2 • Sponsor: Douglas Mental Health University Institute • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
New weekly shot aims to shed pounds in obesity trial
Disease control Recruiting nowThis is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a rati…
Phase: PHASE3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New blood test could replace surgery for endometriosis diagnosis
Diagnosis Recruiting nowEndometriosis (EMS) is a common gynecological disease that affects 176 million girls and women globally. EMS affects 5-10% of women and adolescents within the reproductive age range of 15-49 years, and for those facing infertility, this figure may climb up to 50%. EMS can start a…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
CtDNA test guides chemo to stop rectal cancer return
Disease control Recruiting nowThe goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery. The main research question the REACT study aims to answer is: \- Does adjuvant chemot…
Phase: PHASE3 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
Disease control Recruiting nowThe purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).
Phase: PHASE2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for angelman syndrome: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThe main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.
Phase: PHASE2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo shows promise against tough head and neck cancer
Disease control Recruiting nowThe primary objective of this study is to compare the objective response rate (ORR) of patients with LA-HNSCC, treated with induction of EGFR-ADC MRG003 and anti PD-1 Pucotenlimab versus EGFR-ADC MRG003 alone before chemoradiotherapy. People eligible to participate in this study…
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for leukemia patients: olverembatinib trial launches
Disease control Recruiting nowTo learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New mRNA vaccine trial aims to stop genital herpes
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONA Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
Phase: PHASE1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic …
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Immune cell boost plus targeted procedure shows promise for inoperable liver tumors
Disease control Not yet recruitingThis is a Phase II, open-label, randomized, multicenter study to evaluate the efficacy and safety of GKL-006 combine with TACE in adult patients with unresectable Hepatocellular carcinoma.
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for Hard-to-Treat cervical cancer? drug trial targets HER2
Disease control Recruiting nowThis study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study is a prospective, multicenter, single-arm, exploratory study. 30 patients with locally advanced HR+/HER2- breast cancer who have not received any treatment were recruited to receive apalutamide voraparib combined with chemotherapy for neoadjuvant therapy. This study ad…
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC